FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms

Narcolepsy type 1 is a rare, lifelong neuropsychiatric sleep disorder affecting about 1 in 2,000 people in the U.S. It is caused by the loss of brain cells that produce orexin, a chemical messenger regulating wakefulness, sleep, and muscle tone. Without orexin, patients experience excessive daytime sleepiness, cataplexy, sleep paralysis, hallucinations, and disrupted nighttime sleep. Until now, no medicine had been approved for the condition as a unified disorder, and none acted on the orexin system.

Orzeyful (oveporexton) is an oral tablet taken twice daily that directly activates the same brain receptor orexin would normally stimulate, restoring the missing signal rather than masking symptoms with stimulants or sedatives. Its efficacy and safety were evaluated in two randomized, double-blind, placebo-controlled 12-week studies enrolling 273 adults with narcolepsy type 1.

In both studies, patients taking Orzeyful 2 mg showed improvements in the ability to stay awake during the day, substantially less daytime sleepiness, a significant reduction in cataplexy episodes, and meaningful improvement across the full spectrum of narcolepsy symptoms, including sleep paralysis, hallucinations, and disrupted nighttime sleep. The most common side effects were insomnia, increased urinary frequency, urgency to urinate, and increased saliva production; the rate of discontinuation due to side effects was low. Orzeyful should not be used with strong CYP3A inhibitors.

The FDA's Tiffany R. Farchione called it "the first medicine that impacts the underlying biology of the disease, treating narcolepsy type 1 as a whole." This approval marks a shift from treating individual symptoms to addressing the root cause of the disorder.